The implanted medical device developer “Sanyou Medical” has received a new round of financing of 100 million yuan, which is exclusively funded by Yingke Capital.

Recently, Shanghai Sanyou Medical Devices Co., Ltd. (hereinafter referred to as “Sanyou Medical”) announced that it has obtained a new round of financing of 100 million yuan, which will be exclusively funded by Yingke Capital and will receive a board seat of Sanyou Medical. It is reported that this round of financing will be mainly used for product development and channel construction. So far, Sanyou Medical has completed the first round of financing after MBO (Management Acquisition).

According to public information, Sanyou Medical was established in April 2005. It is an orthopaedic implanted medical device developer dedicated to the research, development, production and sales of orthopedic implants. The company's flagship brand Tuteng laboratory and its international research and development The team has established a sound product development system. In the past five years, Sanyou Medical has obtained 21 invention patents and 48 utility model patents, and applied for 3 foreign invention patents.

According to Liu Mingyan, Chairman of Sanyou Medical, Tuo Teng Lab is an international standard research and development center. Sanyou Medical can cooperate with top domestic orthopedic experts and scientific research units to develop new products. Among them, its self-developed minimally invasive spinal internal fixation products were developed by Sanyou Medical and domestic experts. In June 2016, the “Z series Spinal Minimally Invasive Surgery Device”, which was developed by Sanyou Medical Center, was the first in the country. It can count the time required for doctors to wear the rod in seconds, which reduces the patient’s surrounding tissue during surgery. trauma.

At the same time, Liu Mingyan said, "In the early days of establishment, most of the products that dominated the Chinese orthopaedic market came from overseas brands. The development of domestic orthopaedic enterprises over the years relied on counterfeiting imported brands. The core technology and pricing power of orthopedic products have always been in the hands of foreign companies. Faced with this situation, the development of China's orthopedics needs to embark on a road of independent innovation, and Sanyou Medical is one of the domestic high-end medical device manufacturers that broke this situation. It is also the development of orthopedic devices for domestic independent research and development capabilities. One of the production companies."

In recent years, the income of Sanyou Medical has maintained rapid growth. The sales revenue in the first half of this year increased by nearly 30% year-on-year. Among them, the growth of spine business increased by more than 30% year-on-year, and corporate profits increased steadily. It is reported that Sanyou Medical has completed the share reform in the first half of 2016 and started the IPO process in the domestic capital market. According to Yingke Capital, the financing also promoted the IPO process to a certain extent.

In terms of financing history, in June 2014, Sanyou Medical received a financing of more than 10 million US dollars from Qiming Venture Capital and Taifu Capital. Hu Xubo, a partner of Qiming Venture Partners, joined the board of directors of Sanyou as an investor. Regarding the financing, Sanyou Medical said, “The exclusive investment in the introduction of Yingke Capital is most valued by the vision and long-term commitment of Yingke Capital in the medical field, and can provide support for Sanyou Medical in terms of strategy and management.”

It is understood that Zisheng Yingke Capital was founded in 2010 and is a research organization focusing on Pre-IPO investment strategy. In the high-end medical field, Yingke Capital also focuses on finding leading companies in the sub-sectors in the pharmaceutical industry. Its investment companies mainly include Xinlikang, Besida, Tianzhu Technology, Puris, and Keshi Medical. At present, Yingke Capital has invested in nearly 30 pharmaceutical or medical device companies, accounting for nearly 20% of the total investment projects.

Sun Jun, deputy director of Yingke Capital Investment, said, “The future development direction of Sanyou Medical is also the most optimistic of Yingke Capital. It is to continue to enhance the ability of product research and development and innovation. The investment in research and development of Sanyou Medical has exceeded 40 million yuan. In the future, Sanyou is not excluded. The possibility of medical mergers and acquisitions upstream of the industry."

Fish Sauce

Zhejiang Industrial Group Co., Ltd. , https://www.xingyeseafood.com